Center for Life Sciences Innovation
ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play. The Center’s mission is to study and advance the many technology, economic, and policy factors underpinning successful life sciences innovation—from how new technologies like artificial intelligence, genomics, and gene editing are powering the next generation of biomedical innovation to the economics of life sciences innovation, including the role of IP and incentives therein; international competitiveness in life sciences innovation; and foremost the optimal set of public policies, at home and abroad, to spur greater levels of much-needed biopharmaceutical innovation.
- Read more about the Center.
- Stay up to date by signing up for ITIF’s weekly email and checking the box to get information about “Life Sciences.”
The Economics of Biopharmaceutical Innovation: Symposium Report
How Japan Squandered Its Biopharmaceutical Competitiveness: A Cautionary Tale
Testimony to the Senate Finance Committee on “Prescription Drug Price Inflation”
Going, Going, Gone? To Stay Competitive in Biopharmaceuticals, America Must Learn From Its Semiconductor Mistakes
Five Fatal Flaws in Rep. Katie Porter’s Indictment of the U.S. Drug Industry
April 4, 2023
Lessons From the Rise and Fall of Japan’s Life-Sciences Innovation Ecosystem
Tune in for an expert panel discussion examining where Japan faltered in this sector, what it must do to restore its life-sciences innovation leadership and competitiveness, why that would be in the best interests of both Japan and the United States—and what America must do to avoid following in Japan’s footsteps.
March 24, 2023
Preserving a Virtuous Cycle: The Economics of Biopharmaceutical Innovation
Watch the release event of a new report that examines the dynamics that underpin the economics of biopharmaceutical innovation and how to maintain a supportive environment that keeps the United States in the lead of life-sciences innovation.
March 29, 2022
How Using March-in Rights Would Threaten America’s Research Universities
ITIF hosted a panel discussion with leading experts on innovation policy, technology transfer, and business, who spoke to the practical implications of exercising federal “march-in” rights and why it would be a grave and ill-timed mistake for the U.S. health, competitiveness, and research landscape.
April 29, 2021
How Intellectual Property Has Played a Pivotal Role in the Global COVID-19 Response
ITIF hosted an expert panel discussion about the report and the vital role IP has played throughout the pandemic.
April 21, 2021
Seizing the Transformative Opportunity of Multi-cancer Early Detection
ITIF hosted an expert panel discussion exploring the groundbreaking innovations and policy considerations impacting the field of multi-cancer early detection.
Vice President, Global Innovation Policy, and Director, Center for Life Sciences Innovation
Policy Analyst, Economics of Biopharmaceutical Innovation
Associate Vice President for Federal Affairs, University of Pennsylvania
Managing Director, Bay City Capital
Partner, Irell & Manella, LLP
Cain Brothers & Company Professor of Healthcare, Columbia University Graduate School of Business
Assistant Professor of Medicine, Harvard Medical School
Founding President and CEO, National Minority Quality Forum
More From the Center
March 30, 2023|Testimonies & Filings
Testimony to the US International Trade Commission Regarding COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities
A TRIPS IPR waiver for COVID-19 diagnostics and therapeutics is unnecessary, unwarranted, and even counterproductive—just as it was for COVID-19 vaccines.
January 25, 2023|Reports & Briefings
How Off-Label Use of Medicines Drives Health-Care Use and Disability
Peer-reviewed research finds that pharmaceutical innovation provides direct and indirect benefits for health-care use and disability.
August 5, 2022|Blogs & Features
Senate Reconciliation Legislation Fails to Reconcile the Interests of Biomedical Innovation and Drug Price Affordability
The bill fails to recognize three critical realities: 1) that drug prices are, in fact, not a significant driver of raging inflation; 2) that there exist better mechanisms to reform Medicare Part D drug pricing practices; 3) that mandated government price controls do inflict serious harm on nations’ life-sciences innovation systems.
July 8, 2022|Blogs & Features
Senate Democrats’ Drug Price Proposal Would Slow the Pace of New Drug Discovery
Congress should ignore pressure from progressive activists who want to use drug price controls to move to a government-led drug discovery and production system and instead focus on more pragmatic reforms.
June 24, 2022|Blogs & Features
Postmortem on a Pyrrhic Victory for IP Foes at the WTO
The WTO’s approval of a TRIPS waiver for IP related to COVID-19 vaccines is essentially a shotgun blast completely missing the broadside of a barn.
June 17, 2022|Blogs & Features
No, America’s Drug Prices Aren’t Climbing Radically Out of Control
The United States uniquely leads the world in innovating new drugs and getting them to patients first while sustaining a globally competitive industry and over time making drugs affordable by incentivizing competition and creating generic pathways.
June 6, 2022|Publications
About ITIF’s Center for Life Sciences Innovation
ITIF’s Center for Life Sciences Innovation advocates for accelerating biopharmaceutical innovation by recognizing that the public and private sectors both have essential roles to play in advancing the technology, economic, and policy factors that underpin it.